-
1
-
-
33846414720
-
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary
-
Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007;28(1):88-126
-
(2007)
Eur Heart J
, vol.28
, Issue.1
, pp. 88-126
-
-
Ryden, L.1
Standl, E.2
Bartnik, M.3
-
2
-
-
77955657267
-
Insulin resistance lipotoxicity type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009
-
DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53(7):1270-87
-
(2010)
Diabetologia
, vol.53
, Issue.7
, pp. 1270-87
-
-
Defronzo, R.A.1
-
3
-
-
54749114466
-
It's not how fat you are, it's what you do with it that counts
-
Virtue S, Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biol 2008;6(9):1819-23
-
(2008)
PLoS Biol
, vol.6
, Issue.9
, pp. 1819-23
-
-
Virtue, S.1
Vidal-Puig, A.2
-
4
-
-
19944366619
-
Regulation of plasma triglycerides in insulin resistance and diabetes
-
Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 2005;36(3):232-40
-
(2005)
Arch Med Res
, vol.36
, Issue.3
, pp. 232-40
-
-
Ginsberg, H.N.1
Zhang, Y.L.2
Hernandez-Ono, A.3
-
6
-
-
43449108812
-
Economic costs of diabetes in the U.S. in 2007
-
Anonymous
-
Anonymous. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31(3):596-615
-
(2008)
Diabetes Care
, vol.31
, Issue.3
, pp. 596-615
-
-
-
7
-
-
77649156851
-
Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus
-
Blonde L. Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med 2010;123(3A):S12-18
-
(2010)
Am J Med
, vol.123
, Issue.3 A
-
-
Blonde, L.1
-
8
-
-
33845405222
-
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
-
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-43
-
(2006)
N Engl J Med
, vol.355
, Issue.23
, pp. 2427-43
-
-
Kahn, S.E.1
Haffner, S.M.2
Heise, M.A.3
-
9
-
-
77949833491
-
Diabetes and cardiovascular disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD ADVANCE VADT UKPDS PROactive and NICE-SUGAR
-
Schernthaner G. Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wien Med Wochenschr 2010;160(1-2):8-19
-
(2010)
Wien Med Wochenschr
, vol.160
, Issue.1-2
, pp. 8-19
-
-
Schernthaner, G.1
-
10
-
-
78649308905
-
-
Available from [Cited]
-
Charlish P. 2010. Available from: http://www. scripclinicalresearch.com/ therapeutics/Diabetes-sector-continues-to-generate-immense-interest-297521? autnRef=/contentstore/gcpj/codex/b61e1963-79ed-11df-870a-bbcce1c03e31.xml [Cited]
-
(2010)
-
-
Charlish, P.1
-
11
-
-
77953529312
-
Insulin resistance in nonalcoholic fatty liver disease
-
Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010;16(17):1941-51
-
(2010)
Curr Pharm des
, vol.16
, Issue.17
, pp. 1941-1951
-
-
Bugianesi, E.1
Moscatiello, S.2
Ciaravella, M.F.3
Marchesini, G.4
-
13
-
-
65349177200
-
AMPK: An emerging drug target for diabetes and the metabolic syndrome
-
Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009;9(5):407-16
-
(2009)
Cell Metab
, vol.9
, Issue.5
, pp. 407-16
-
-
Zhang, B.B.1
Zhou, G.2
Li, C.3
-
14
-
-
78649261863
-
-
Merck Sharp & Dohme Corp.; Metabasis Therapeutics Inc. WO2010051176
-
Merck Sharp & Dohme Corp.; Metabasis Therapeutics, Inc. WO2010051176; 2010
-
(2010)
-
-
-
15
-
-
78649250581
-
-
Merck Sharp & Dohme Corp. WO2010047982
-
Merck Sharp & Dohme Corp. WO2010047982; 2010
-
(2010)
-
-
-
16
-
-
78649299830
-
-
TransTech Pharma Inc. 2009111700
-
TransTech Pharma, Inc. 2009111700; 2009
-
(2009)
-
-
-
17
-
-
78649263678
-
-
Astellas Pharma Inc. WO2009041521
-
Astellas Pharma, Inc. WO2009041521; 2009
-
(2009)
-
-
-
18
-
-
78649308463
-
-
Pfizer Inc WO2008084300
-
Pfizer, Inc. WO2008084300. 2008
-
(2008)
-
-
-
19
-
-
78649295730
-
-
F. Hoffman-La Roche AG. US2008300279
-
F. Hoffman-La Roche AG. US2008300279; 2008
-
(2008)
-
-
-
20
-
-
78649291452
-
-
F. Hoffmann-La Roche AG. WO2008074692
-
F. Hoffmann-La Roche AG. WO2008074692; 2008
-
(2008)
-
-
-
21
-
-
78649274790
-
-
F. Hoffmann-La Roche AG. US2009270505
-
F. Hoffmann-La Roche AG. US2009270505; 2009
-
(2009)
-
-
-
22
-
-
78649304584
-
-
F. Hoffmann-La Roche AG. WO2009270500
-
F. Hoffmann-La Roche AG. WO2009270500; 2009
-
(2009)
-
-
-
23
-
-
78649237300
-
-
Sirtris Pharmaceuticals Inc. WO2010019606
-
Sirtris Pharmaceuticals, Inc. WO2010019606; 2010
-
(2010)
-
-
-
24
-
-
36248975293
-
SIRT1 transgenic mice show phenotypes resembling calorie restriction
-
Bordone L, Cohen D, Robinson A, et al. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 2007;6(6):759-67
-
(2007)
Aging Cell
, vol.6
, Issue.6
, pp. 759-67
-
-
Bordone, L.1
Cohen, D.2
Robinson, A.3
-
25
-
-
78649255306
-
-
F. Hoffmann-La Roche AG. WO2008003611
-
F. Hoffmann-La Roche AG. WO2008003611; 2008
-
(2008)
-
-
-
26
-
-
78649307617
-
-
F. Hoffmann-La Roche AG. WO2009132986
-
F. Hoffmann-La Roche AG. WO2009132986; 2009
-
(2009)
-
-
-
27
-
-
78649251506
-
-
F. Hoffmann-La Roche AG. WO2010006940
-
F. Hoffmann-La Roche AG. WO2010006940; 2010
-
(2010)
-
-
-
28
-
-
78649273068
-
-
F. Hoffmann-La Roche AG. US2008293756
-
F. Hoffmann-La Roche AG. US2008293756; 2008
-
(2008)
-
-
-
29
-
-
78649243548
-
-
F. Hoffmann-La Roche AG. WO2008037628
-
F. Hoffmann-La Roche AG. WO2008037628; 2008
-
(2008)
-
-
-
30
-
-
78649283580
-
-
F. Hoffmann-La Roche AG. WO2010052144
-
F. Hoffmann-La Roche AG. WO2010052144; 2010
-
(2010)
-
-
-
31
-
-
12244288887
-
Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin
-
Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005;90(1):359-65
-
(2005)
J Clin Endocrinol Metab
, vol.90
, Issue.1
, pp. 359-65
-
-
Korner, J.1
Bessler, M.2
Cirilo, L.J.3
-
32
-
-
78649311675
-
-
Merck Sharp & Dohme Corp WO2010053830
-
Merck Sharp & Dohme Corp. WO2010053830; 2010
-
(2010)
-
-
-
33
-
-
46749086605
-
Recent progress in the discovery of selective, non-peptide ligands of somatostatin receptors
-
Wolkenberg SE, Thut CJ. Recent progress in the discovery of selective, non-peptide ligands of somatostatin receptors. Curr Opin Drug Discov Devel 2008;11(4):446-57
-
(2008)
Curr Opin Drug Discov Devel
, vol.11
, Issue.4
, pp. 446-57
-
-
Wolkenberg, S.E.1
Thut, C.J.2
-
34
-
-
78649314535
-
-
Merck & Co., Inc. WO2008051272
-
Merck & Co., Inc. WO2008051272; 2008
-
(2008)
-
-
-
35
-
-
78649309767
-
-
Merck & Co., Inc. WO2009011836
-
Merck & Co., Inc. WO2009011836; 2009
-
(2009)
-
-
-
36
-
-
78649232775
-
-
Merck Sharp & Dohme Corp. WO2010056717
-
Merck Sharp & Dohme Corp. WO2010056717; 2010
-
(2010)
-
-
-
37
-
-
78649287443
-
-
Merck & Co., Inc. US2009131451
-
Merck & Co., Inc. US2009131451; 2009
-
(2009)
-
-
-
38
-
-
78649276085
-
-
Merck & Co., Inc.; Banyu Pharmaceutical Co. Ltd. WO2008088692
-
Merck & Co., Inc.; Banyu Pharmaceutical Co. Ltd. WO2008088692; 2008
-
(2008)
-
-
-
39
-
-
78649240314
-
-
Merck & Co., Inc. WO2008039327
-
Merck & Co., Inc. WO2008039327; 2008
-
(2008)
-
-
-
40
-
-
78649260982
-
-
Banyu Pharmaceutical Co., Ltd. WO2009038021
-
Banyu Pharmaceutical Co., Ltd. WO2009038021; 2009
-
(2009)
-
-
-
41
-
-
78649311674
-
-
Merck Frosst Canada Ltd. WO2010025553
-
Merck Frosst Canada Ltd. WO2010025553; 2010
-
(2010)
-
-
-
42
-
-
72249113143
-
Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438)
-
Leger S, Black WC, Deschenes D, et al. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438). Bioorg Med Chem Lett 2010;20(2):499-502
-
(2010)
Bioorg Med Chem Lett
, vol.20
, Issue.2
, pp. 499-502
-
-
Leger, S.1
Black, W.C.2
Deschenes, D.3
-
43
-
-
78649306294
-
-
Medicinal Chemistry Gordon Conference. Available from [Cited]
-
Medicinal Chemistry Gordon Conference. Available from: http://www. grc.org/programs.aspx? year=2010&program=medchem [Cited]
-
-
-
-
44
-
-
48749112588
-
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family
-
Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 2008;38(7-8):778-801
-
(2008)
Xenobiotica
, vol.38
, Issue.7-8
, pp. 778-801
-
-
Hagenbuch, B.1
Gui, C.2
-
45
-
-
78649255788
-
-
Merck Frosst Canada Ltd. WO2008046226
-
Merck Frosst Canada Ltd. WO2008046226; 2008
-
(2008)
-
-
-
46
-
-
78649253539
-
-
Merck Frosst Canada Ltd. WO2009073973
-
Merck Frosst Canada Ltd. WO2009073973; 2009
-
(2009)
-
-
-
47
-
-
78649246908
-
-
Merck Frosst Canada Ltd. WO2009012573
-
Merck Frosst Canada Ltd. WO2009012573; 2009
-
(2009)
-
-
-
48
-
-
77649192401
-
Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6
-
Shimamura K, Nagumo A, Miyamoto Y et al. Discovery and characterization of a novel potent, selective and orally active inhibitor for mammalian ELOVL6. Eur J Pharmacol 2010;630(1-3):34-41
-
(2010)
Eur J Pharmacol
, vol.630
, Issue.1-3
, pp. 34-41
-
-
Shimamura, K.1
Nagumo, A.2
Miyamoto, Y.3
-
49
-
-
0034773404
-
Role of AMP-activated protein kinase in mechanism of metformin action
-
Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108(8):1167-74
-
(2001)
J Clin Invest
, vol.108
, Issue.8
, pp. 1167-74
-
-
Zhou, G.1
Myers, R.2
Li, Y.3
-
51
-
-
78649299829
-
-
Wyeth John and Brother Ltd US2009163474
-
Wyeth, John, and Brother Ltd. US2009163474; 2009
-
(2009)
-
-
-
52
-
-
78649292739
-
-
Pfizer Inc WO2010013161
-
Pfizer, Inc. WO2010013161; 2010
-
(2010)
-
-
-
53
-
-
62749205848
-
The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis
-
Cariou B. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab 2008;34(6 Pt 2):685-91
-
(2008)
Diabetes Metab
, vol.34
, Issue.6 PART 2
, pp. 685-91
-
-
Cariou, B.1
-
54
-
-
78649300670
-
-
Wyeth John and Brother Ltd WO2008100627
-
Wyeth, John, and Brother Ltd. WO2008100627; 2008
-
(2008)
-
-
-
56
-
-
78649278151
-
-
Sanofi-Aventis Deutschland G.m.b.H. WO2008006496
-
Sanofi-Aventis Deutschland G.m.b.H. WO2008006496; 2008
-
(2008)
-
-
-
57
-
-
78649241273
-
-
Sanofi-Aventis Deutschland G.m.b.H. WO2010043566
-
Sanofi-Aventis Deutschland G.m.b.H. WO2010043566; 2010
-
(2010)
-
-
-
58
-
-
78649306760
-
-
Sanofi-Aventis. WO2009149820
-
Sanofi-Aventis. WO2009149820; 2009
-
(2009)
-
-
-
59
-
-
78649286536
-
-
Sanofi-Aventis. WO2008000950
-
Sanofi-Aventis. WO2008000950; 2008
-
(2008)
-
-
-
60
-
-
78649278152
-
-
Sanofi-Aventis. WO2008135141
-
Sanofi-Aventis. WO2008135141; 2008
-
(2008)
-
-
-
61
-
-
78649244420
-
-
Sanofi-Aventis. EP2023144
-
Sanofi-Aventis. EP2023144; 2009
-
(2009)
-
-
-
62
-
-
78649313667
-
-
Takeda Pharmaceutical Co. Ltd. WO2008121592
-
Takeda Pharmaceutical Co. Ltd. WO2008121592; 2008
-
(2008)
-
-
-
63
-
-
78649296169
-
-
Takeda Pharmaceutical Co. Ltd. WO2008136428
-
Takeda Pharmaceutical Co. Ltd. WO2008136428; 2008
-
(2008)
-
-
-
64
-
-
78649231907
-
-
Takeda Pharmaceutical Co. Ltd. WO2008011131
-
Takeda Pharmaceutical Co. Ltd. WO2008011131; 2008
-
(2008)
-
-
-
65
-
-
78649270780
-
-
Takeda Pharmaceutical Co. Ltd. WO2008067465
-
Takeda Pharmaceutical Co. Ltd. WO2008067465; 2008
-
(2008)
-
-
-
66
-
-
78649274380
-
-
Takeda Pharmaceutical Co. Ltd. WO2008001931
-
Takeda Pharmaceutical Co. Ltd. WO2008001931; 2008
-
(2008)
-
-
-
67
-
-
78649251024
-
-
Takeda Pharmaceutical Co. Ltd. WO2008044767
-
Takeda Pharmaceutical Co. Ltd. WO2008044767; 2008
-
(2008)
-
-
-
68
-
-
78649255304
-
-
Takeda Pharmaceutical Co. Ltd. WO2009110520
-
Takeda Pharmaceutical Co. Ltd. WO2009110520; 2009
-
(2009)
-
-
-
69
-
-
78649244839
-
-
Takeda Pharmaceutical Co. Ltd. WO2009057784
-
Takeda Pharmaceutical Co. Ltd. WO2009057784; 2009
-
(2009)
-
-
-
70
-
-
78649240313
-
-
Takeda Pharmaceutical Co. Ltd. WO2008143262
-
Takeda Pharmaceutical Co. Ltd. WO2008143262; 2008
-
(2008)
-
-
-
71
-
-
78649254849
-
-
Takeda Pharmaceutical Co. Ltd. WO2010001869
-
Takeda Pharmaceutical Co. Ltd. WO2010001869; 2010
-
(2010)
-
-
-
72
-
-
78649238994
-
-
Takeda Pharmaceutical Co. Ltd. WO2008016131
-
Takeda Pharmaceutical Co. Ltd. WO2008016131; 2008
-
(2008)
-
-
-
73
-
-
78649242119
-
-
Takeda Pharmaceutical Co. Ltd. WO2008010511
-
Takeda Pharmaceutical Co. Ltd. WO2008010511; 2008
-
(2008)
-
-
-
74
-
-
78649273066
-
-
Takeda Pharmaceutical Co. Ltd. WO2009145286
-
Takeda Pharmaceutical Co. Ltd. WO2009145286; 2009
-
(2009)
-
-
-
75
-
-
33745325873
-
Impact of mitochondrial reactive oxygen species and apoptosis signal-regulating kinase 1 on insulin signaling
-
Imoto K, Kukidome D, Nishikawa T, et al. Impact of mitochondrial reactive oxygen species and apoptosis signal-regulating kinase 1 on insulin signaling. Diabetes 2006;55(5):1197-204
-
(2006)
Diabetes
, vol.55
, Issue.5
, pp. 1197-204
-
-
Imoto, K.1
Kukidome, D.2
Nishikawa, T.3
-
76
-
-
1542357667
-
The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity
-
Xu J, Wang P, Li Y, et al. The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity. Proc Natl Acad Sci USA 2004;101(9):3112-17
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, Issue.9
, pp. 3112-17
-
-
Xu, J.1
Wang, P.2
Li, Y.3
-
77
-
-
78649294386
-
-
Bionomics Ltd. WO2008040057
-
Bionomics Ltd. WO2008040057; 2008
-
(2008)
-
-
-
78
-
-
78649307167
-
-
Bionomics Ltd. WO2009043117
-
Bionomics Ltd. WO2009043117; 2009
-
(2009)
-
-
-
79
-
-
78649299417
-
-
Arena Pharmaceuticals Inc.; Merck & Co. WO2010030360
-
Arena Pharmaceuticals, Inc.; Merck & Co. WO2010030360; 2010
-
(2010)
-
-
-
80
-
-
24744448667
-
Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal
-
Abu-Elheiga L, Matzuk MM, Kordari P, et al. Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc Natl Acad Sci USA 2005;102(34):12011-16
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, Issue.34
, pp. 12011-16
-
-
Abu-Elheiga, L.1
Matzuk, M.M.2
Kordari, P.3
-
81
-
-
33744781581
-
Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis
-
Mao J, DeMayo FJ, Li H, et al. Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc Natl Acad Sci USA 2006;103(22):8552-7
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, Issue.22
, pp. 8552-7
-
-
Mao, J.1
Demayo, F.J.2
Li, H.3
-
82
-
-
33644654777
-
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2
-
Savage DB, Choi CS, Samuel VT, et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J Clin Invest 2006;116(3):817-24
-
(2006)
J Clin Invest
, vol.116
, Issue.3
, pp. 817-24
-
-
Savage, D.B.1
Choi, C.S.2
Samuel, V.T.3
-
83
-
-
0035970805
-
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2
-
Abu-Elheiga L, Matzuk MM, Abo-Hashema KA, Wakil SJ. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 2001;291(5513):2613-16
-
(2001)
Science
, vol.291
, Issue.5513
, pp. 2613-16
-
-
Abu-Elheiga, L.1
Matzuk, M.M.2
Abo-Hashema, K.A.3
Wakil, S.J.4
-
84
-
-
0042337449
-
Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets
-
Abu-Elheiga L, Oh W, Kordari P, Wakil SJ. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high- carbohydrate diets. Proc Natl Acad Sci USA 2003;100(18):10207-12
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, Issue.18
, pp. 10207-12
-
-
Abu-Elheiga, L.1
Oh, W.2
Kordari, P.3
Wakil, S.J.4
-
85
-
-
36749052873
-
Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity
-
Choi CS, Savage DB, Abu-Elheiga L, et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci USA 2007;104(42):16480-5
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, Issue.42
, pp. 16480-5
-
-
Choi, C.S.1
Savage, D.B.2
Abu-Elheiga, L.3
-
86
-
-
13444265891
-
Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice
-
Oh W, Abu-Elheiga L, Kordari P, et al. Glucose and fat metabolism in adipose tissue of acetyl-CoA carboxylase 2 knockout mice. Proc Natl Acad Sci USA 2005;102(5):1384-9
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, Issue.5
, pp. 1384-9
-
-
Oh, W.1
Abu-Elheiga, L.2
Kordari, P.3
-
87
-
-
72649089588
-
Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity
-
Hoehn KL, Turner N, Swarbrick MM, et al. Acute or chronic upregulation of mitochondrial fatty acid oxidation has no net effect on whole-body energy expenditure or adiposity. Cell Metab 2010;11(1):70-6
-
(2010)
Cell Metab
, vol.11
, Issue.1
, pp. 70-6
-
-
Hoehn, K.L.1
Turner, N.2
Swarbrick, M.M.3
-
88
-
-
77952213776
-
Gene knockout of Acc2 has little effect on body weight fat mass or food intake
-
Olson DP, Pulinilkunnil T, Cline GW, et al. Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake. Proc Natl Acad Sci USA 2010;107(16):7598-603
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, Issue.16
, pp. 7598-603
-
-
Olson, D.P.1
Pulinilkunnil, T.2
Cline, G.W.3
-
89
-
-
50549202600
-
The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus
-
Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1(7285):785-9
-
(1963)
Lancet
, vol.1
, Issue.7285
, pp. 785-9
-
-
Randle, P.J.1
Garland, P.B.2
Hales, C.N.3
Newsholme, E.A.4
-
90
-
-
0141510051
-
Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis and increase fatty acid oxidation in cultured cells and in experimental animals
-
Harwood HJ Jr, Petras SF, Shelly LD, et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 2003;278(39):37099-111
-
(2003)
J Biol Chem
, vol.278
, Issue.39
, pp. 37099-111
-
-
Harwood Jr., H.J.1
Petras, S.F.2
Shelly, L.D.3
-
91
-
-
67650462508
-
Review of recent acetyl-CoA carboxylase inhibitor patents: Mid-2007-2008
-
Corbett JW. Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008. Expert Opin Ther Pat 2009;19(7):943-56
-
(2009)
Expert Opin Ther Pat
, vol.19
, Issue.7
, pp. 943-56
-
-
Corbett, J.W.1
-
92
-
-
0025341608
-
The mechanism by which rat liver glucokinase is inhibited by the regulatory protein
-
Vandercammen A, Van Schaftingen E. The mechanism by which rat liver glucokinase is inhibited by the regulatory protein. Eur J Biochem 1990;191(2):483-9
-
(1990)
Eur J Biochem
, vol.191
, Issue.2
, pp. 483-9
-
-
Vandercammen, A.1
Van Schaftingen, E.2
-
93
-
-
0031851588
-
The physiological role of glucokinase binding and translocation in hepatocytes
-
Agius L. The physiological role of glucokinase binding and translocation in hepatocytes. Adv Enzyme Regul 1998;38:303-31
-
(1998)
Adv Enzyme Regul
, vol.38
, pp. 303-31
-
-
Agius, L.1
-
94
-
-
67349139275
-
Assessing the potential of glucokinase activators in diabetes therapy
-
Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009;8(5):399-416
-
(2009)
Nat Rev Drug Discov
, vol.8
, Issue.5
, pp. 399-416
-
-
Matschinsky, F.M.1
-
95
-
-
0024342083
-
Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans
-
Iynedjian PB, Pilot PR, Nouspikel T, et al. Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans. Proc Natl Acad Sci USA 1989;86(20):7838-42
-
(1989)
Proc Natl Acad Sci USA
, vol.86
, Issue.20
, pp. 7838-42
-
-
Iynedjian, P.B.1
Pilot, P.R.2
Nouspikel, T.3
-
96
-
-
0036303140
-
Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons
-
Dunn-Meynell AA, Routh VH, Kang L, et al. Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons. Diabetes 2002;51(7):2056-65
-
(2002)
Diabetes
, vol.51
, Issue.7
, pp. 2056-65
-
-
Dunn-Meynell, A.A.1
Routh, V.H.2
Kang, L.3
-
97
-
-
56449093424
-
Glucose sensing in L cells: A primary cell study
-
Reimann F, Habib AM, Tolhurst G, et al. Glucose sensing in L cells: a primary cell study. Cell Metab 2008;8(6):532-9
-
(2008)
Cell Metab
, vol.8
, Issue.6
, pp. 532-9
-
-
Reimann, F.1
Habib, A.M.2
Tolhurst, G.3
-
98
-
-
49649099805
-
Glucokinase and molecular aspects of liver glycogen metabolism
-
Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008;414(1):1-18
-
(2008)
Biochem J
, vol.414
, Issue.1
, pp. 1-18
-
-
Agius, L.1
-
99
-
-
0035787576
-
Cell-specific roles of glucokinase in glucose homeostasis
-
Postic C, Shiota M, Magnuson MA. Cell-specific roles of glucokinase in glucose homeostasis. Rec Prog Horm Res 2001;56:195-217
-
(2001)
Rec Prog Horm Res
, vol.56
, pp. 195-217
-
-
Postic, C.1
Shiota, M.2
Magnuson, M.A.3
-
100
-
-
70350741368
-
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia
-
Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat 2009;30(11):1512-26
-
(2009)
Hum Mutat
, vol.30
, Issue.11
, pp. 1512-26
-
-
Osbak, K.K.1
Colclough, K.2
Saint-Martin, C.3
-
101
-
-
0037624071
-
Allosteric activators of glucokinase: Potential role in diabetes therapy
-
Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003;301(5631):370-3
-
(2003)
Science
, vol.301
, Issue.5631
, pp. 370-3
-
-
Grimsby, J.1
Sarabu, R.2
Corbett, W.L.3
-
102
-
-
78049512890
-
Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: A mechanistic study
-
Available at
-
Bonadonna RC, Heise T, Arbet-Engels C, et al. Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 2010;95(11). Available at http://jcem.endojournals.org/cgi/reprint/jc.2010-1041v1
-
(2010)
J Clin Endocrinol Metab
, vol.95
, Issue.11
-
-
Bonadonna, R.C.1
Heise, T.2
Arbet-Engels, C.3
-
103
-
-
48049120189
-
Glucokinase activators as new type 2 diabetes therapeutic agents
-
Sarabu R, Berthel SJ, Kester RF, Tilley JW. Glucokinase activators as new type 2 diabetes therapeutic agents. Expert Opin Ther Pat 2008;18(7):759-68
-
(2008)
Expert Opin Ther Pat
, vol.18
, Issue.7
, pp. 759-68
-
-
Sarabu, R.1
Berthel, S.J.2
Kester, R.F.3
Tilley, J.W.4
-
104
-
-
0037838892
-
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids
-
Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 2003;278(13):11303-11
-
(2003)
J Biol Chem
, vol.278
, Issue.13
, pp. 11303-11
-
-
Briscoe, C.P.1
Tadayyon, M.2
Andrews, J.L.3
-
105
-
-
0037434991
-
Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40
-
Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003;422(6928):173-6
-
(2003)
Nature
, vol.422
, Issue.6928
, pp. 173-6
-
-
Itoh, Y.1
Kawamata, Y.2
Harada, M.3
-
106
-
-
33846327180
-
GPR40 is expressed in glucagon producing cells and affects glucagon secretion
-
Flodgren E, Olde B, Meidute-Abaraviciene S, et al. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem Biophys Res Commun 2007;354(1):240-5
-
(2007)
Biochem Biophys Res Commun
, vol.354
, Issue.1
, pp. 240-5
-
-
Flodgren, E.1
Olde, B.2
Meidute-Abaraviciene, S.3
-
107
-
-
20944433543
-
The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse
-
Steneberg P, Rubins N, Bartoov-Shifman R, et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 2005;1(4):245-58
-
(2005)
Cell Metab
, vol.1
, Issue.4
, pp. 245-58
-
-
Steneberg, P.1
Rubins, N.2
Bartoov-Shifman, R.3
-
108
-
-
33745607930
-
Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: Identification of agonist and antagonist small molecules
-
Briscoe CP, Peat AJ, McKeown SC, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 2006;148(5):619-28
-
(2006)
Br J Pharmacol
, vol.148
, Issue.5
, pp. 619-28
-
-
Briscoe, C.P.1
Peat, A.J.2
McKeown, S.C.3
-
109
-
-
53849146735
-
The long-chain fatty acid receptor GPR40, and glucolipotoxicity: Investigations using GPR40-knockout mice
-
Brownlie R, Mayers RM, Pierce JA, et al. The long-chain fatty acid receptor, GPR40, and glucolipotoxicity: investigations using GPR40-knockout mice. Biochem Soc Trans 2008;36(Pt 5):950-4
-
(2008)
Biochem Soc Trans
, vol.36
, Issue.PART 5
, pp. 950-4
-
-
Brownlie, R.1
Mayers, R.M.2
Pierce, J.A.3
-
110
-
-
34047177401
-
GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo
-
Latour MG, Alquier T, Oseid E, et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007;56(4):1087-94
-
(2007)
Diabetes
, vol.56
, Issue.4
, pp. 1087-94
-
-
Latour, M.G.1
Alquier, T.2
Oseid, E.3
-
111
-
-
50949128408
-
Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice
-
Tan CP, Feng Y, Zhou YP, et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008;57(8):2211-19
-
(2008)
Diabetes
, vol.57
, Issue.8
, pp. 2211-19
-
-
Tan, C.P.1
Feng, Y.2
Zhou, Y.P.3
-
112
-
-
52249093427
-
The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding
-
Kebede M, Alquier T, Latour MG, et al. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008;57(9):2432-7
-
(2008)
Diabetes
, vol.57
, Issue.9
, pp. 2432-7
-
-
Kebede, M.1
Alquier, T.2
Latour, M.G.3
-
113
-
-
65549096659
-
Poitout V. GPR40: Good cop, bad cop?
-
Alquier T, Poitout V. GPR40: good cop, bad cop? Diabetes 2009;58(5):1035-6
-
(2009)
Diabetes
, vol.58
, Issue.5
, pp. 1035-6
-
-
Alquier, T.1
-
114
-
-
65549114432
-
Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice
-
Nagasumi K, Esaki R, Iwachidow K, et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009;58(5):1067-76
-
(2009)
Diabetes
, vol.58
, Issue.5
, pp. 1067-76
-
-
Nagasumi, K.1
Esaki, R.2
Iwachidow, K.3
-
115
-
-
67649331670
-
Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): An emerging target for type 2 diabetes
-
Bharate SB, Nemmani KVS, Vishwakarma RA. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes. Expert Opin Ther Pat 2009;19(2):237-64
-
(2009)
Expert Opin Ther Pat
, vol.19
, Issue.2
, pp. 237-64
-
-
Bharate, S.B.1
Kvs, N.2
Vishwakarma, R.A.3
-
116
-
-
10644275303
-
Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor
-
Soga T, Ohishi T, Matsui T, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 2005;326(4):744-51
-
(2005)
Biochem Biophys Res Commun
, vol.326
, Issue.4
, pp. 744-51
-
-
Soga, T.1
Ohishi, T.2
Matsui, T.3
-
117
-
-
33644627958
-
Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents
-
Overton HA, Babbs AJ, Doel SM, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006;3(3):167-75
-
(2006)
Cell Metab
, vol.3
, Issue.3
, pp. 167-75
-
-
Overton, H.A.1
Babbs, A.J.2
Doel, S.M.3
-
118
-
-
34248527678
-
A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release
-
Chu ZL, Jones RM, He H, et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007;148(6):2601-9
-
(2007)
Endocrinology
, vol.148
, Issue.6
, pp. 2601-9
-
-
Chu, Z.L.1
Jones, R.M.2
He, H.3
-
119
-
-
51849099001
-
Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119
-
Semple G, Fioravanti B, Pereira G, et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem 2008;51(17):5172-5
-
(2008)
J Med Chem
, vol.51
, Issue.17
, pp. 5172-5
-
-
Semple, G.1
Fioravanti, B.2
Pereira, G.3
-
120
-
-
52749098923
-
Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion
-
Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008;57(9):2280-7
-
(2008)
Diabetes
, vol.57
, Issue.9
, pp. 2280-7
-
-
Edfalk, S.1
Steneberg, P.2
Edlund, H.3
-
121
-
-
67649913243
-
GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis
-
Lan H, Vassileva G, Corona A, et al. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 2009;201(2):219-30
-
(2009)
J Endocrinol
, vol.201
, Issue.2
, pp. 219-30
-
-
Lan, H.1
Vassileva, G.2
Corona, A.3
-
122
-
-
42449126696
-
A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release
-
Chu ZL, Carroll C, Alfonso J, et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 2008;149(5):2038-47
-
(2008)
Endocrinology
, vol.149
, Issue.5
, pp. 2038-47
-
-
Chu, Z.L.1
Carroll, C.2
Alfonso, J.3
-
123
-
-
65549142522
-
GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell
-
Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 2009;58(5):1058-66
-
(2009)
Diabetes
, vol.58
, Issue.5
, pp. 1058-66
-
-
Lauffer, L.M.1
Iakoubov, R.2
Brubaker, P.L.3
-
124
-
-
58149464981
-
Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells
-
Parker HE, Habib AM, Rogers GJ, et al. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009;52(2):289-98
-
(2009)
Diabetologia
, vol.52
, Issue.2
, pp. 289-98
-
-
Parker, H.E.1
Habib, A.M.2
Rogers, G.J.3
-
125
-
-
70349770172
-
GPR119 agonists for the treatment of type 2 diabetes
-
Jones RM, Leonard JN, Buzard DJ, Lehmann J. GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat 2009;19(10):1339-59
-
(2009)
Expert Opin Ther Pat
, vol.19
, Issue.10
, pp. 1339-59
-
-
Jones, R.M.1
Leonard, J.N.2
Buzard, D.J.3
Lehmann, J.4
-
126
-
-
85047683614
-
Minireview: 11beta-hydroxysteroid dehydrogenase type 1 - A tissue-specific amplifier of glucocorticoid action
-
Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001;142(4):1371-6
-
(2001)
Endocrinology
, vol.142
, Issue.4
, pp. 1371-6
-
-
Seckl, J.R.1
Walker, B.R.2
-
127
-
-
73249141243
-
11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation
-
Cooper MS, Stewart PM. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009;94(12):4645-54
-
(2009)
J Clin Endocrinol Metab
, vol.94
, Issue.12
, pp. 4645-54
-
-
Cooper, M.S.1
Stewart, P.M.2
-
128
-
-
0026095840
-
The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization
-
Tannin GM, Agarwal AK, Monder C, et al. The human gene for 11 beta-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 1991;266(25):16653-8
-
(1991)
J Biol Chem
, vol.266
, Issue.25
, pp. 16653-8
-
-
Tannin, G.M.1
Agarwal, A.K.2
Monder, C.3
-
129
-
-
0030936556
-
Does central obesity reflect "cushing's disease of the omentum"?
-
Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997;349(9060):1210-13
-
(1997)
Lancet
, vol.349
, Issue.9060
, pp. 1210-13
-
-
Bujalska, I.J.1
Kumar, S.2
Stewart, P.M.3
-
130
-
-
0027159080
-
Human placental 11 beta-hydroxysteroid dehydrogenase: Evidence for and partial purification of a distinct NAD-dependent isoform
-
Brown RW, Chapman KE, Edwards CR, Seckl JR. Human placental 11 beta-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. Endocrinology 1993;132(6):2614-21
-
(1993)
Endocrinology
, vol.132
, Issue.6
, pp. 2614-21
-
-
Brown, R.W.1
Chapman, K.E.2
Edwards, C.R.3
Seckl, J.R.4
-
131
-
-
0024445143
-
The kidney is the major site of cortisone production in man
-
Whitworth JA, Stewart PM, Burt D, et al. The kidney is the major site of cortisone production in man. Clin Endocrinol (Oxf) 1989;31(3):355-61
-
(1989)
Clin Endocrinol (Oxf)
, vol.31
, Issue.3
, pp. 355-61
-
-
Whitworth, J.A.1
Stewart, P.M.2
Burt, D.3
-
132
-
-
0028034209
-
Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme
-
Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994;105(2):R11-17
-
(1994)
Mol Cell Endocrinol
, vol.105
, Issue.2
-
-
Albiston, A.L.1
Obeyesekere, V.R.2
Smith, R.E.3
Krozowski, Z.S.4
-
133
-
-
0035051205
-
Tissue-specific dysregulation of cortisol metabolism in human obesity
-
Rask E, Olsson T, Soderberg S, et al. Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001;86(3):1418-21
-
(2001)
J Clin Endocrinol Metab
, vol.86
, Issue.3
, pp. 1418-21
-
-
Rask, E.1
Olsson, T.2
Soderberg, S.3
-
134
-
-
0035824440
-
A transgenic model of visceral obesity and the metabolic syndrome
-
Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294(5549):2166-70
-
(2001)
Science
, vol.294
, Issue.5549
, pp. 2166-70
-
-
Masuzaki, H.1
Paterson, J.2
Shinyama, H.3
-
135
-
-
0031283178
-
11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress
-
Kotelevtsev Y, Holmes MC, Burchell A, et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997;94(26):14924-9
-
(1997)
Proc Natl Acad Sci USA
, vol.94
, Issue.26
, pp. 14924-9
-
-
Kotelevtsev, Y.1
Holmes, M.C.2
Burchell, A.3
-
136
-
-
0035798621
-
Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice
-
Morton NM, Holmes MC, Fievet C, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001;276(44):41293-300
-
(2001)
J Biol Chem
, vol.276
, Issue.44
, pp. 41293-300
-
-
Morton, N.M.1
Holmes, M.C.2
Fievet, C.3
-
137
-
-
0036882136
-
Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity
-
Tomlinson JW, Sinha B, Bujalska I, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002;87(12):5630-5
-
(2002)
J Clin Endocrinol Metab
, vol.87
, Issue.12
, pp. 5630-5
-
-
Tomlinson, J.W.1
Sinha, B.2
Bujalska, I.3
-
138
-
-
42149162795
-
11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity
-
Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs 2008;17(4):481-96
-
(2008)
Expert Opin Investig Drugs
, vol.17
, Issue.4
, pp. 481-96
-
-
Hughes, K.A.1
Webster, S.P.2
Walker, B.R.3
-
139
-
-
0036432995
-
Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice
-
Alberts P, Engblom L, Edling N, et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002;45(11):1528-32
-
(2002)
Diabetologia
, vol.45
, Issue.11
, pp. 1528-32
-
-
Alberts, P.1
Engblom, L.2
Edling, N.3
-
140
-
-
0242468543
-
Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains
-
Alberts P, Nilsson C, Selen G, et al. Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003;144(11):4755-62
-
(2003)
Endocrinology
, vol.144
, Issue.11
, pp. 4755-62
-
-
Alberts, P.1
Nilsson, C.2
Selen, G.3
-
141
-
-
2342510149
-
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice
-
Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 2004;101(18):7088-93
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, Issue.18
, pp. 7088-93
-
-
Paterson, J.M.1
Morton, N.M.2
Fievet, C.3
-
142
-
-
77955590502
-
11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes
-
Morgan SA, Tomlinson JW. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2010;19(9):1067-76
-
(2010)
Expert Opin Investig Drugs
, vol.19
, Issue.9
, pp. 1067-76
-
-
Morgan, S.A.1
Tomlinson, J.W.2
-
143
-
-
0037238379
-
Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes
-
Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003;88(1):285-91
-
(2003)
J Clin Endocrinol Metab
, vol.88
, Issue.1
, pp. 285-91
-
-
Andrews, R.C.1
Rooyackers, O.2
Walker, B.R.3
-
144
-
-
0028839840
-
Carbenoxolone increases hepatic insulin sensitivity in man: A novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation
-
Walker BR, Connacher AA, Lindsay RM, et al. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995;80(11):3155-9
-
(1995)
J Clin Endocrinol Metab
, vol.80
, Issue.11
, pp. 3155-9
-
-
Walker, B.R.1
Connacher, A.A.2
Lindsay, R.M.3
-
145
-
-
64549162134
-
-
American Diabetes Association 68th Scientific Sessions; 6-10 June 2008; San Francisco, CA
-
Hawkins M, Hunter D, Kishore P, et al. INCB013739, a selective inhibitor of 11b-hydroxysteroid dehydrogenase type 1 (11bHSD1), improves insulin sensitivity and lowers plasma cholesterol over 28 days in patients with type 2 diabetes mellitus. American Diabetes Association 68th Scientific Sessions; 6-10 June 2008; San Francisco, CA; 2008
-
(2008)
INCB013739 A Selective Inhibitor of 11b-hydroxysteroid Dehydrogenase Type 1 (11bHSD1) Improves Insulin Sensitivity and Lowers Plasma Cholesterol over 28 Days in Patients with Type 2 Diabetes Mellitus
-
-
Hawkins, M.1
Hunter, D.2
Kishore, P.3
-
146
-
-
77955836270
-
17beta-Hydroxysteroid dehydrogenase inhibitors: A patent review
-
Poirier D. 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review. Expert Opin Ther Pat 2010;20(9):1123-45
-
(2010)
Expert Opin Ther Pat
, vol.20
, Issue.9
, pp. 1123-45
-
-
Poirier, D.1
-
147
-
-
0037143752
-
Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity
-
Ntambi JM, Miyazaki M, Stoehr JP, et al. Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA 2002;99(17):11482-6
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, Issue.17
, pp. 11482-6
-
-
Ntambi, J.M.1
Miyazaki, M.2
Stoehr, J.P.3
-
148
-
-
0141813781
-
Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle
-
Rahman SM, Dobrzyn A, Dobrzyn P, et al. Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle. Proc Natl Acad Sci USA 2003;100(19):11110-15
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, Issue.19
, pp. 11110-15
-
-
Rahman, S.M.1
Dobrzyn, A.2
Dobrzyn, P.3
-
149
-
-
12144268751
-
Stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen accumulation in brown adipose tissue
-
Rahman SM, Dobrzyn A, Lee SH, et al. Stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen accumulation in brown adipose tissue. Am J Physiol Endocrinol Metab 2005;288(2):E381-7
-
(2005)
Am J Physiol Endocrinol Metab
, vol.288
, Issue.2
-
-
Rahman, S.M.1
Dobrzyn, A.2
Lee, S.H.3
-
150
-
-
4644340815
-
Lack of stearoyl-CoA desaturase 1 upregulates basal thermogenesis but causes hypothermia in a cold environment
-
Lee SH, Dobrzyn A, Dobrzyn P, et al. Lack of stearoyl-CoA desaturase 1 upregulates basal thermogenesis but causes hypothermia in a cold environment. J Lipid Res 2004;45(9):1674-82
-
(2004)
J Lipid Res
, vol.45
, Issue.9
, pp. 1674-82
-
-
Lee, S.H.1
Dobrzyn, A.2
Dobrzyn, P.3
-
151
-
-
34047269605
-
Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat
-
Sampath H, Miyazaki M, Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat. J Biol Chem 2007;282(4):2483-93
-
(2007)
J Biol Chem
, vol.282
, Issue.4
, pp. 2483-93
-
-
Sampath, H.1
Miyazaki, M.2
Dobrzyn, A.3
Ntambi, J.M.4
-
152
-
-
63249121641
-
Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver
-
Kotronen A, Seppanen-Laakso T, Westerbacka J, et al. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009;58(1):203-8
-
(2009)
Diabetes
, vol.58
, Issue.1
, pp. 203-8
-
-
Kotronen, A.1
Seppanen-Laakso, T.2
Westerbacka, J.3
-
153
-
-
64049110523
-
Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis
-
Arendt BM, Mohammed SS, Aghdassi E, et al. Hepatic fatty acid composition differs between chronic hepatitis C patients with and without steatosis. J Nutr 2009;139(4):691-5
-
(2009)
J Nutr
, vol.139
, Issue.4
, pp. 691-5
-
-
Arendt, B.M.1
Mohammed, S.S.2
Aghdassi, E.3
-
154
-
-
41149102818
-
Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans
-
Stefan N, Peter A, Cegan A, et al. Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans. Diabetologia 2008;51(4):648-56
-
(2008)
Diabetologia
, vol.51
, Issue.4
, pp. 648-56
-
-
Stefan, N.1
Peter, A.2
Cegan, A.3
-
155
-
-
78649242535
-
-
Glenmark Pharmaceuticals S.A. WO2010035052
-
Glenmark Pharmaceuticals, S.A. WO2010035052; 2010
-
(2010)
-
-
-
156
-
-
64749094872
-
Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose
-
Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951;30(2):125-9
-
(1951)
J Clin Invest
, vol.30
, Issue.2
, pp. 125-9
-
-
Farber, S.J.1
Berger, E.Y.2
Earle, D.P.3
-
157
-
-
0028044629
-
The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose
-
Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93(1):397-404
-
(1994)
J Clin Invest
, vol.93
, Issue.1
, pp. 397-404
-
-
Kanai, Y.1
Lee, W.S.2
You, G.3
-
158
-
-
0034997336
-
Renal Na(+)-glucose cotransporters
-
Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280(1):F10-18
-
(2001)
Am J Physiol Renal Physiol
, vol.280
, Issue.1
-
-
Wright, E.M.1
-
159
-
-
0036937335
-
Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)
-
Van Den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002;111(6):544-7
-
(2002)
Hum Genet
, vol.111
, Issue.6
, pp. 544-7
-
-
Van Den Heuvel, L.P.1
Assink, K.2
Willemsen, M.3
Monnens, L.4
-
160
-
-
10744229025
-
Molecular analysis of the SGLT2 gene in patients with renal glucosuria
-
Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14(11):2873-82
-
(2003)
J Am Soc Nephrol
, vol.14
, Issue.11
, pp. 2873-82
-
-
Santer, R.1
Kinner, M.2
Lassen, C.L.3
-
161
-
-
1142263153
-
Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria
-
Calado J, Soto K, Clemente C, et al. Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum Genet 2004;114(3):314-16
-
(2004)
Hum Genet
, vol.114
, Issue.3
, pp. 314-16
-
-
Calado, J.1
Soto, K.2
Clemente, C.3
-
162
-
-
12744253796
-
Phlorizin: A review
-
Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21(1):31-8
-
(2005)
Diabetes Metab Res Rev
, vol.21
, Issue.1
, pp. 31-8
-
-
Ehrenkranz, J.R.1
Lewis, N.G.2
Kahn, C.R.3
Roth, J.4
-
163
-
-
0023275573
-
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats
-
Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79(5):1510-15
-
(1987)
J Clin Invest
, vol.79
, Issue.5
, pp. 1510-15
-
-
Rossetti, L.1
Smith, D.2
Shulman, G.I.3
-
164
-
-
0032850016
-
T-1095, an inhibitor of renal Na +-glucose cotransporters, may provide a novel approach to treating diabetes
-
Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na +-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48(9):1794-800
-
(1999)
Diabetes
, vol.48
, Issue.9
, pp. 1794-800
-
-
Oku, A.1
Ueta, K.2
Arakawa, K.3
-
165
-
-
33845873376
-
Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level
-
Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007;320(1):323-30
-
(2007)
J Pharmacol Exp Ther
, vol.320
, Issue.1
, pp. 323-30
-
-
Katsuno, K.1
Fujimori, Y.2
Takemura, Y.3
-
166
-
-
64549093267
-
Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats
-
Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009;609(1-3):148-54
-
(2009)
Eur J Pharmacol
, vol.609
, Issue.1-3
, pp. 148-54
-
-
Fujimori, Y.1
Katsuno, K.2
Ojima, K.3
-
167
-
-
52649083832
-
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
-
Fujimori Y, Katsuno K, Nakashima I, et al. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008;327(1):268-76
-
(2008)
J Pharmacol Exp Ther
, vol.327
, Issue.1
, pp. 268-76
-
-
Fujimori, Y.1
Katsuno, K.2
Nakashima, I.3
-
168
-
-
77953734934
-
Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus
-
Hussey EK, Clark RV, Amin DM, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010;50(6):623-35
-
(2010)
J Clin Pharmacol
, vol.50
, Issue.6
, pp. 623-35
-
-
Hussey, E.K.1
Clark, R.V.2
Amin, D.M.3
-
169
-
-
74949093195
-
Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents
-
Washburn WN. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Pat 2009;19(11):1485-99
-
(2009)
Expert Opin Ther Pat
, vol.19
, Issue.11
, pp. 1485-99
-
-
Washburn, W.N.1
|